Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Taking Cues From Nature En Route To Paclitaxel

ACS Meeting News: Synthesis of an intermediate along the way to the cancer drug opens avenues to novel analogs

by Bethany Halford
March 24, 2014 | A version of this story appeared in Volume 92, Issue 12

No one is better than nature at making the cancer drug paclitaxel (Taxol). But synthetic chemists would like to learn from nature. By mimicking the early steps in paclitaxel’s biosynthesis, a team at Scripps Research Institute, La Jolla, Calif., has potentially come up with a way to create analogs of paclitaxel that are unavailable via bioengineering. These could turn out to be powerful drugs as well. A team led by Phil S. Baran synthesized the natural product (–)-taxuyunnanine D in just five steps from taxadiene. The transformation mimics the first three of eight oxidations that occur biosynthetically when taxadiene is converted to paclitaxel. Taxuyunnanine D, Baran said, could ultimately be used as an intermediate en route to paclitaxel. The challenge for Baran’s group was to control the order of the three oxidations. It’s a tough task, Baran explained, because taxadiene is a strained, doubly unsaturated hydrocarbon that is “spring-loaded” for oxidation at several spots at once. Through computational modeling, developing a seldom-used chromium reagent, and conducting hundreds of reactions, Baran’s team executed the early steps of paclitaxel’s biosynthesis (J. Am. Chem. Soc. 2014, DOI: 10.1021/ja501782r).

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.